Holding(s) in Company

RNS Number : 1837R

Yourgene Health PLC

26 February 2019

 

TR-1: Standard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i
1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:			Yourgene Health plc
1b. Please indicate if the issuer is a non-UK issuer  (please mark with an "X" if appropriate)
Non-UK issuer
2. Reason for the notification (please mark the appropriate box or boxes with an "X")
An acquisition or disposal of voting rights						X
An acquisition or disposal of financial instruments
An event changing the breakdown of voting rights						X
Other (please specify)iii:
3. Details of person subject to the notification obligationiv
Name			Life Technologies Limited, a company incorporated in Scotland with company number SC083107
City and country of registered office (if applicable)
4. Full name of shareholder(s) (if different from 3.)v
Name
City and country of registered office (if applicable)
5. Date on which the threshold was crossed or reachedvi:			22 February 2019
6. Date on which issuer notified (DD/MM/YYYY):			26 February 2019
7. Total positions of person(s) subject to the notification obligation
	% of voting rights attached to shares (total of 8. A)	% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)		Total of both in % (8.A + 8.B)	Total number of voting rights of issuervii
Resulting situation on the date on which threshold was crossed or reached	9.01% (based on current share capital) and 8.06% (based on so-enlarged share capital)	11.84% based on current share capi-tal) and 10.58% (based on so-enlarged share capital)		20.85% based on current share capital) and 18.64% (based on so-enlarged share capital)	458,999,688 (based on current share capital) and 513,332,229 (based on so-enlarged share capital)
Position of previous notification (if applicable)	N/A	29.79% (based on current share capital) and 22.95% (based on so-enlarged share capital)		N/A

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii
A: Voting rights attached to shares
Class/type of shares ISIN code (if possible)		Number of voting rightsix					% of voting rights
		Direct (Art 9 of Directive 2004/109/EC) (DTR5.1)		Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1)			Direct (Art 9 of Directive 2004/109/EC) (DTR5.1)		Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1)
Ordinary Shares of 0.1 pence each GB00BN31ZD89		41,356,165		0			9.01% (based on current share capital) and 8.06% (based on so-enlarged share capital)		0%
SUBTOTAL 8. A		41,356,165					9.01% (based on current share capital) and 8.06% (based on so-enlarged share capital)
B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))
Type of financial instrument		Expiration datex	Exercise/ Conversion Periodxi			Number of voting rights that may be acquired if the instrument is exercised/converted.			% of voting rights
			SUBTOTAL 8. B 1
B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))
Type of financial instrument	Expiration datex		Exercise/ Conversion Period xi		Physical or cash settlementxii			Number of voting rights	% of voting rights
Warrants	11 December 2023		Exercisable up to 11 December 2023		Physical			20,325,204	4.43% (based on current share capital) and 3.96% (based on so-enlarged share capital)
Warrants	11 December 2023		Exercisable up to 11 December 2023		Physical			17,094,018	3.72% (based on current share capital) and 3.33% (based on so-enlarged share capital)
Warrants	11 December 2023		Exercisable up to 11 December 2023		Physical			16,913,319	3.68% (based on current share capital) and 3.29% (based on so-enlarged share capital)
					SUBTOTAL 8.B.2			54,332,541	11.84% based on current share capital) and 10.58% (based on so-enlarged share capital)

9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an "X")
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii
Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)				X
Namexv	% of voting rights if it equals or is higher than the notifiable threshold	% of voting rights through financial instruments if it equals or is higher than the notifiable threshold	Total of both if it equals or is higher than the notifiable threshold
Thermo Fisher Scientific Inc.	9.01% (based on current share capital) and 8.06% (based on so-enlarged share capital)	11.84% based on current share capital) and 10.58% (based on so-enlarged share capital)	20.85% based on current share capital) and 18.64% (based on so-enlarged share capital)
Thermo Fisher Scientific Life Holdings Limited	9.01% (based on current share capital) and 8.06% (based on so-enlarged share capital)	11.84% based on current share capital) and 10.58% (based on so-enlarged share capital)	20.85% based on current share capital) and 18.64% (based on so-enlarged share capital)
Life Technologies Limited	9.01% (based on current share capital) and 8.06% (based on so-enlarged share capital)	11.84% based on current share capital) and 10.58% (based on so-enlarged share capital)	20.85% based on current share capital) and 18.64% (based on so-enlarged share capital)
10. In case of proxy voting, please identify:
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be held
11. Additional informationxvi
Subscription by Life Technologies Limited for new ordinary shares in the issuer pursuant to the exercise of warrants over 28,938,797 ordinary shares at 10.73 pence per share and warrants over 12,417,368 ordinary shares at 5.78 per share.

Place of completion	London, United Kingdom
Date of completion	22 February 2019

 

END

 

 

HOLTFMATMBBTBPL